30652-11-0 | 3-Hydroxy-1,2-dimethyl-4(1h)-pyridone

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$6.00	$4.00
5g	98%	in stock	$20.00	$14.00

Description

• Catalog Number: AB40761
• Chemical Name: 3-Hydroxy-1,2-dimethyl-4(1h)-pyridone
• CAS Number: 30652-11-0
• Molecular Formula: C7H9NO2
• Molecular Weight: 139.1519
• MDL Number: MFCD00129690
• SMILES: Cn1ccc(=O)c(c1C)O
• NSC Number: 758880

Computed Properties

• Complexity: 228
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 10
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• XLogP3: 0.5

Literature

• Kupffer cell depletion protects against the steatosis, but not the liver damage, induced by marginal-copper, high-fructose diet in male rats.

  American journal of physiology. Gastrointestinal and liver physiology 20150601

• Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.

  PloS one 20130101

• Development of a fast LC-MS/MS assay for the determination of deferiprone in human plasma and application to pharmacokinetics.

  Biomedical chromatography : BMC 20121201

• How I treat transfusional iron overload.

  Blood 20121101

• Iron chelation therapy in the management of transfusion-related cardiac iron overload.

  Transfusion 20121001

• Chelation of aluminum by combining deferasirox and deferiprone in rats.

  Toxicology and industrial health 20120901

• Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.

  Annals of hematology 20120901

• Amelioration of metal-induced toxicity in Caenorhabditis elegans: utility of chelating agents in the bioremediation of metals.

  Toxicological sciences : an official journal of the Society of Toxicology 20120901

• Hydroxy(thio)pyrone and hydroxy(thio)pyridinone iron chelators: physico-chemical properties and anti-oxidant activity.

  Journal of inorganic biochemistry 20120901

• Iron(III)-doped, silica nanoshells: a biodegradable form of silica.

  Journal of the American Chemical Society 20120829

• Pantothenate kinase-associated neurodegeneration.

  Current drug targets 20120801

• Deferiprone is superior to deferasirox and desferrioxamine in cardiac iron overload.

  Indian pediatrics 20120801

• Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina.

  Free radical biology & medicine 20120701

• Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.

  American journal of hematology 20120701

• New drugs 2012, part 2.

  Nursing 20120701

• Evaluation of the binding of oxovanadium(IV) to human serum albumin.

  Dalton transactions (Cambridge, England : 2003) 20120607

• Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

  Haematologica 20120601

• Iron mobilization using chelation and phlebotomy.

  Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 20120601

• Update on a patient with superficial siderosis on deferiprone.

  AJNR. American journal of neuroradiology 20120601

• The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.

  Hematology (Amsterdam, Netherlands) 20120501

• Ferric complexes of 3-hydroxy-4-pyridinones characterized by density functional theory and Raman and UV-vis spectroscopies.

  Inorganic chemistry 20120416

• Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study.

  Pakistan journal of pharmaceutical sciences 20120401

• Synthesis, physicochemical properties and antioxidant activity of deferiprone-cyclodextrin conjugates and their iron(III) complexes.

  Dalton transactions (Cambridge, England : 2003) 20120314

• Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake.

  Journal of medicinal chemistry 20120308

• Circulating CD133(+)VEGFR2 (+) and CD34 (+)VEGFR2 (+) cells and arterial function in patients with beta-thalassaemia major.

  Annals of hematology 20120301

• Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models.

  Disease models & mechanisms 20120301

• Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features.

  North American journal of medical sciences 20120301

• Thalassemia major: the present and the future.

  North American journal of medical sciences 20120301

• Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.

  International journal of preventive medicine 20120301

• Deferiprone (Ferriprox) for iron overload.

  The Medical letter on drugs and therapeutics 20120220

• Deferasirox for managing iron overload in people with thalassaemia.

  The Cochrane database of systematic reviews 20120215

• Quercetin as a shuttle for labile iron.

  Journal of inorganic biochemistry 20120201

• Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation.

  Parkinsonism & related disorders 20120101

• Determination of deferiprone in urine and serum using a terbium-sensitized luminescence method.

  Luminescence : the journal of biological and chemical luminescence 20120101

• Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.

  Stroke 20120101

• Invasive mold infections: virulence and pathogenesis of mucorales.

  International journal of microbiology 20120101

• Use of deferiprone for the treatment of hepatic iron storage disease in three hornbills.

  Journal of the American Veterinary Medical Association 20120101

• Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20120101

• Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation.

  PloS one 20120101

• Chemosensitization as a means to augment commercial antifungal agents.

  Frontiers in microbiology 20120101

• Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

  Journal of Alzheimer's disease : JAD 20120101

• Impaired iron status in aging research.

  International journal of molecular sciences 20120101

• A unique modification of the eukaryotic initiation factor 5A shows the presence of the complete hypusine pathway in Leishmania donovani.

  PloS one 20120101

• Chelating agents for the treatment of systemic iron overload.

  Current medicinal chemistry 20120101

• Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice.

  PloS one 20120101

• Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.

  Hemoglobin 20120101

• Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model.

  PloS one 20120101

• Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in Beta thalassemia major patients: a review of the literature.

  Anemia 20120101

• The Association between Myocardial Iron Load and Ventricular Repolarization Parameters in Asymptomatic Beta-Thalassemia Patients.

  Advances in hematology 20120101

• Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.

  Pharmacology 20120101

• Determinants of pulmonary hypertension in patients with Beta-thalassemia major and normal ventricular function.

  Acta haematologica 20120101

• Treating thalassemia major-related iron overload: the role of deferiprone.

  Journal of blood medicine 20120101

• Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.

  Toxicology 20111118

• Deferiprone approved for iron overload.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111115

• FDA panel recommends approval of deferiprone.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20111108

• A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.

  Haematologica 20111101

• Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.

  International immunopharmacology 20111101

• Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.

  Journal of paediatrics and child health 20111101

• Challenges of adherence and persistence with iron chelation therapy.

  International journal of hematology 20111101

• As iron goes, so goes disease?

  Haematologica 20111101

• Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

  Blood cells, molecules & diseases 20111015

• Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.

  European journal of haematology 20111001

• Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.

  European journal of haematology 20111001

• Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.

  European journal of haematology 20111001

• Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

  Blood transfusion = Trasfusione del sangue 20111001

• Past, present & future scenario of thalassaemic care & control in India.

  The Indian journal of medical research 20111001

• How I treat thalassemia.

  Blood 20110929

• Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

  British journal of pharmacology 20110901

• Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.

  British journal of haematology 20110901

• Chelation treatment in sickle-cell-anaemia: much ado about nothing?

  British journal of haematology 20110901

• Allosteric effects of sulfonate anions on the rates of iron release from serum transferrin.

  Journal of inorganic biochemistry 20110901

• Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints.

  Heart (British Cardiac Society) 20110815

• Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial.

  Movement disorders : official journal of the Movement Disorder Society 20110801

• A synopsis of current care of thalassaemia major patients in Hong Kong.

  Hong Kong medical journal = Xianggang yi xue za zhi 20110801

• Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.

  Internal medicine journal 20110701

• Iron chelation therapy and thalassemia - an overview.

  Mymensingh medical journal : MMJ 20110701

• Health-related quality of life in Thai thalassemic children treated with iron chelation.

  The Southeast Asian journal of tropical medicine and public health 20110701

• Recent advances in β-thalassemias.

  Pediatric reports 20110616

• Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.

  Blood cells, molecules & diseases 20110615

• Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

  Transfusion 20110501

• Chelation of cadmium by combining deferasirox and deferiprone in rats.

  Toxicology and industrial health 20110501

• In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.

  Experimental parasitology 20110501

• Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G.

  Inorganic chemistry 20110418

• Quercetin-iron chelates are transported via glucose transporters.

  Free radical biology & medicine 20110415

• Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.

  Canadian journal of physiology and pharmacology 20110401

• Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.

  Cerebellum (London, England) 20110301

• Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study.

  Pediatric blood & cancer 20110301

• Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).

  European journal of haematology 20110301

• Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.

  Hematology (Amsterdam, Netherlands) 20110301

• The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.

  Investigative ophthalmology & visual science 20110201

• Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.

  Journal of neural transmission (Vienna, Austria : 1996) 20110201

• Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.

  Haematologica 20110201

• Iron chelation in thalassemia: time to reconsider our comfort zones.

  Expert review of hematology 20110201

• Iron overload and allogeneic hematopoietic stem-cell transplantation.

  Expert review of hematology 20110201

• Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

  Haematologica 20110101

• Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.

  Clinical pharmacokinetics 20110101

• Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.

  AJNR. American journal of neuroradiology 20110101

• Iron and mechanisms of neurotoxicity.

  International journal of Alzheimer's disease 20110101

• Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20110101

• Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.

  Annals of tropical paediatrics 20110101

• The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

  International journal of molecular sciences 20110101

• Value of black blood T2* cardiovascular magnetic resonance.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• Uptake of non-transferrin iron by erythroid cells.

  Anemia 20110101

• Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94.

  Biochimica et biophysica acta 20110101

• The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.

  Hemoglobin 20110101

• Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.

  Hemoglobin 20110101

• Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.

  Hemoglobin 20110101

• Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.

  Hemoglobin 20110101

• Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.

  Hemoglobin 20110101

• Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.

  Hemoglobin 20110101

• The effect of the oral iron chelator deferiprone on the liver damage induced by tamoxifen in female rats.

  Hemoglobin 20110101

• 1-(2-Hydroxyethoxy) methyl-2-methyl-3-hydroxyl-4-pyridinone: a targeted, bifunctional chelating agent for potential uranic detoxification in the kidney.

  Hemoglobin 20110101

• Zygomycosis in Immunocompromised non-Haematological Patients.

  Mediterranean journal of hematology and infectious diseases 20110101

• Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.

  Clinical drug investigation 20110101

• Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

  Anemia 20110101

• Epidemiology and treatment approaches in management of invasive fungal infections.

  Clinical epidemiology 20110101

• To 'umbrella' the gonads in transfusion rain.

  Journal of human reproductive sciences 20110101

• Orally active multi-functional antioxidants are neuroprotective in a rat model of light-induced retinal damage.

  PloS one 20110101

• Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

  Pediatric rheumatology online journal 20110101

• Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.

  BMC research notes 20110101

• Comparison of the effect of vanadium and deferoxamine on acetaminophen toxicity in rats.

  Indian journal of pharmacology 20110101

• Iron chelation therapy for transfusional iron overload: a swift evolution.

  Hemoglobin 20110101

• On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

  Advances in pharmacological sciences 20110101

• Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts.

  PloS one 20110101

• Antioxidant Activities of Plumbagin and Its Cu (II) Complex.

  Bioinorganic chemistry and applications 20110101

• Iron and neurodegeneration in multiple sclerosis.

  Multiple sclerosis international 20110101

• Real-world use of iron chelators.

  Hematology. American Society of Hematology. Education Program 20110101

• Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents.

  Research in pharmaceutical sciences 20110101

• Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

  Journal of blood medicine 20110101

• Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

  Journal of hepatology 20101201

• Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

  Hematology/oncology clinics of North America 20101201

• Combining two orally active iron chelators for thalassemia.

  Annals of hematology 20101101

• Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.

  European journal of haematology 20101101

• A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

  Hepatology (Baltimore, Md.) 20101101

• The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.

  Journal of pediatric hematology/oncology 20101101

• The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.

  Expert opinion on drug safety 20101101

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

  Archives of toxicology 20101101

• Recent advances in the treatment of mucormycosis.

  Current infectious disease reports 20101101

• Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.

  European journal of haematology 20101001

• Iron chelation therapy for patients with sickle cell disease and iron overload.

  American journal of hematology 20101001

• An update on disordered iron metabolism and iron overload.

  Hematology (Amsterdam, Netherlands) 20101001

• Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.

  Dalton transactions (Cambridge, England : 2003) 20100828

• Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

  Blood cells, molecules & diseases 20100815

• Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier.

  Journal of medicinal chemistry 20100812

• Deferasirox for managing transfusional iron overload in people with sickle cell disease.

  The Cochrane database of systematic reviews 20100804

• A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.

  Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20100801

• New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.

  British journal of haematology 20100801

• More pieces to the iron chelation puzzle.

  Translational research : the journal of laboratory and clinical medicine 20100801

• Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

  Translational research : the journal of laboratory and clinical medicine 20100801

• Pathogenesis and management of iron toxicity in thalassemia.

  Annals of the New York Academy of Sciences 20100801

• Deferiprone.

  Annals of the New York Academy of Sciences 20100801

• Combined iron chelation therapy.

  Annals of the New York Academy of Sciences 20100801

• Ninth Cooley's Anemia Symposium: summary and perspective.

  Annals of the New York Academy of Sciences 20100801

• The equilibrium between the octahedral and square pyramidal form and the influence of an axial ligand on the molecular properties of V(IV)O complexes: a spectroscopic and DFT study.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20100719

• Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations.

  British journal of cancer 20100713

• Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.

  European journal of haematology 20100701

• Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.

  Expert opinion on drug safety 20100701

• Chelation in metal intoxication.

  International journal of environmental research and public health 20100701

• Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India.

  Asian journal of transfusion science 20100701

• Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

  Chemical research in toxicology 20100621

• Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.

  Diabetologia 20100601

• Amido-3-hydroxypyridin-4-ones as iron(III) ligands.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20100601

• Effect of trace iron levels and iron withdrawal by chelation on the growth of Candida albicans and Candida vini.

  FEMS microbiology letters 20100601

• Daily alternating deferasirox and deferiprone therapy for 'hard-to-chelate' beta-thalassemia major patients.

  American journal of hematology 20100601

• Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.

  Hemoglobin 20100601

• Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.

  Hemoglobin 20100601

• The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.

  Hemoglobin 20100601

• Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.

  Hemoglobin 20100601

• The effect of iron(III) on the activity of selenoenzymes and oxidative damage in the liver of rats. Interaction with natural antioxidants and deferiprone.

  Hemoglobin 20100601

• Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.

  Hemoglobin 20100601

• Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.

  Annals of hematology 20100401

• Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.

  Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20100401

• Iron chelation therapy in myelodysplastic syndromes.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100401

• Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

  Evidence-based complementary and alternative medicine : eCAM 20100301

• Dual-echo TFE MRI for the assessment of myocardial iron overload in beta-thalassemia major patients.

  Diagnostic and interventional radiology (Ankara, Turkey) 20100301

• Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.

  Expert opinion on drug safety 20100301

• Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20100301

• Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.

  Canadian journal of physiology and pharmacology 20100301

• Past, present and future therapeutics for cerebellar ataxias.

  Current neuropharmacology 20100301

• Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients.

  The Korean journal of hematology 20100301

• Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.

  Journal of medicinal chemistry 20100211

• Long-term response to deferiprone therapy in Asian Indians.

  Annals of hematology 20100201

• Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.

  British journal of haematology 20100201

• Vanadate complexes in serum: a speciation modeling study.

  Dalton transactions (Cambridge, England : 2003) 20100107

• New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.

  Inorganic chemistry 20100104

• Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.

  Acta haematologica 20100101

• Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.

  PloS one 20100101

• Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.

  Hemoglobin 20100101

• Iron overload in myelodysplastic syndromes: diagnosis and management.

  Cancer control : journal of the Moffitt Cancer Center 20100101

• Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

  BMC cancer 20100101

• Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.

  Acta haematologica 20100101

• Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.

  Indian journal of ophthalmology 20100101

• Review of Journal of Cardiovascular Magnetic Resonance 2009.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20100101

• Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

  Advances in hematology 20100101

• Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20100101

• Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.

  Acta haematologica 20100101

• Iron overload in sickle cell disease.

  Advances in hematology 20100101

• Beta-thalassemia.

  Orphanet journal of rare diseases 20100101

• beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

  Advances in hematology 20100101

• Deferiprone challenge test for monitoring iron overload in hepatitis positive thalassemic major patients.

  International journal of clinical and experimental medicine 20100101

• Antineoplastic Activity of New Transition Metal Complexes of 6-Methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-Ray Crystal Structures of [VO(2)(mpETSC)] and [Pt(mpETSC)Cl].

  Bioinorganic chemistry and applications 20100101

• Iron chelation therapy in myelodysplastic syndromes.

  Advances in hematology 20100101

• [Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco].

  Revue medicale de Bruxelles 20100101

• Current and emerging treatment options in the management of Friedreich ataxia.

  Neuropsychiatric disease and treatment 20100101

• Iron overload in patients undergoing hematopoietic stem cell transplantation.

  Advances in hematology 20100101

• Hepcidin induces HIV-1 transcription inhibited by ferroportin.

  Retrovirology 20100101

• Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.

  Hematology/oncology and stem cell therapy 20100101

• The pro-BNP Serum Level and Echocardiographic Tissue Doppler Abnormalities in Patients with Beta Thalassemia Major.

  Clinical Medicine Insights. Cardiology 20100101

• Update on iron chelators in thalassemia.

  Hematology. American Society of Hematology. Education Program 20100101

• Effect of Triphaladi Avaleha as an adjuvant therapy in the management of Thalassemia.

  Ayu 20100101

• Contractile and morphological properties of hamster retractor muscle following 16 h of cold preservation.

  Cryobiology 20091201

• Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.

  British journal of haematology 20091201

• The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.

  Journal of biomolecular structure & dynamics 20091201

• Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.

  Haematologica 20091201

• Early cardiac iron overload in children with transfusion-dependent anemias.

  Haematologica 20091201

• The selective quantification of iron by hexadentate fluorescent probes.

  Bioorganic & medicinal chemistry 20091201

• Early detection of iron overload in the heart: a key role for MRI!

  The international journal of cardiovascular imaging 20091201

• Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.

  Blood reviews 20091201

• Optimizing iron chelation strategies in beta-thalassaemia major.

  Blood reviews 20091201

• Synthetic and natural iron chelators: therapeutic potential and clinical use.

  Future medicinal chemistry 20091201

• Iron chelation therapy in the management of thalassemia: the Asian perspectives.

  International journal of hematology 20091101

• The role of iron and iron chelators in zygomycosis.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

• Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20091001

• Skin diseases in patients with beta-thalassemia major.

  International journal of dermatology 20091001

• Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20090901

• Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

  British journal of cancer 20090901

• Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.

  Archives of Iranian medicine 20090901

• A bis(3-hydroxy-4-pyridinone)-EDTA derivative as a strong chelator for M3+ hard metal ions: complexation ability and selectivity.

  Dalton transactions (Cambridge, England : 2003) 20090821

• Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.

  Transfusion 20090801

• Radiation nephropathy is not mitigated by antagonists of oxidative stress.

  Radiation research 20090801

• Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.

  Clinical & experimental optometry 20090701

• Atrial and ventricular function in thalassemic patients with supra-ventricular arrhythmias.

  Heart international 20090630

• Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

  European journal of haematology 20090601

• Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

  European journal of haematology 20090601

• Prospects for introducing deferiprone as potent pharmaceutical antioxidant.

  Frontiers in bioscience (Elite edition) 20090601

• Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.

  JPMA. The Journal of the Pakistan Medical Association 20090601

• Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.

  Free radical research 20090501

• Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.

  International journal of clinical pharmacology and therapeutics 20090501

• Deferiprone-induced arthropathy in thalassemia: MRI findings in a case.

  The Indian journal of radiology & imaging 20090501

• Biospeciation of various antidiabetic V(IV)O compounds in serum.

  Dalton transactions (Cambridge, England : 2003) 20090407

• Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.

  British journal of haematology 20090401

• Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.

  Journal of Korean medical science 20090401

• 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.

  Journal of medicinal chemistry 20090312

• Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier.

  International journal of hematology 20090301

• Cost analysis of iron-related complications in a single institute.

  The Korean journal of internal medicine 20090301

• Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.

  Drug metabolism and disposition: the biological fate of chemicals 20090201

• High doses of deferiprone may be associated with cerebellar syndrome.

  BMJ (Clinical research ed.) 20090122

• Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20090101

• Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

  BMC medical genomics 20090101

• Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.

  PloS one 20090101

• Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

  Blood cells, molecules & diseases 20090101

• Pharmacotherapy for Friedreich ataxia.

  CNS drugs 20090101

• Fatal congestive heart failure with deferiprone.

  Gastroenterologie clinique et biologique 20090101

• The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20090101

• Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia.

  Pediatric hematology and oncology 20090101

• Oral iron chelators.

  Annual review of medicine 20090101

• ER stress-inducible factor CHOP affects the expression of hepcidin by modulating C/EBPalpha activity.

  PloS one 20090101

• Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.

  Clinical lymphoma & myeloma 20090101

• Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.

  Hemoglobin 20090101

• Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.

  Hemoglobin 20090101

• Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.

  Hemoglobin 20090101

• A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.

  Hemoglobin 20090101

• A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.

  Hemoglobin 20090101

• Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient.

  Hemoglobin 20090101

• Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.

  Hemoglobin 20090101

• Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.

  Hemoglobin 20090101

• Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

  Retrovirology 20090101

• Update on the use of deferasirox in the management of iron overload.

  Therapeutics and clinical risk management 20090101

• Deferiprone chelation therapy for thalassemia major.

  Acta haematologica 20090101

• Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.

  PloS one 20090101

• Prevention of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging.

  Advances in hematology 20090101

• Managing myelodysplastic symptoms in elderly patients.

  Clinical interventions in aging 20090101

• Overview of iron chelation therapy with desferrioxamine and deferiprone.

  Hemoglobin 20090101

• Update on survival in thalassemia major.

  Hemoglobin 20090101

• Yersiniabactin reduces the respiratory oxidative stress response of innate immune cells.

  PloS one 20090101

• Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

  Mediterranean journal of hematology and infectious diseases 20090101

• Hematopietic stem cell transplantation in thalassemia and related disorders.

  Mediterranean journal of hematology and infectious diseases 20090101

• Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population.

  Mediterranean journal of hematology and infectious diseases 20090101

• Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.

  Mediterranean journal of hematology and infectious diseases 20090101

• Iron chelation therapy in thalassemia syndromes.

  Mediterranean journal of hematology and infectious diseases 20090101

• Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation.

  Blood 20081215

• Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.

  Current opinion in infectious diseases 20081201

• Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.

  Clinical rheumatology 20081101

• Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.

  Expert opinion on drug safety 20081101

• Current status in iron chelation in hemoglobinopathies.

  Current molecular medicine 20081101

• Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.

  Pediatric endocrinology reviews : PER 20081001

• Treatment of iron overload in thalassemia.

  Pediatric endocrinology reviews : PER 20081001

• Ethnopharmacology.

  Indian journal of pharmacology 20081001

• Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone).

  Oman medical journal 20081001

• Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.

  British journal of haematology 20080901

• Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools.

  Journal of medicinal chemistry 20080814

• Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia.

  Human molecular genetics 20080801

• Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy.

  European journal of haematology 20080801

• Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?

  British journal of haematology 20080801

• Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.

  Advances in therapy 20080801

• Interactions of insulin-mimetic zinc(II) complexes with cell constituents: glutathione and ATP.

  Journal of inorganic biochemistry 20080701

• Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

  Annals of hematology 20080701

• Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.

  Molecular pharmacology 20080701

• Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

  The Journal of pharmacology and experimental therapeutics 20080701

• Alternative treatment paradigm for thalassemia using iron chelators.

  Experimental hematology 20080701

• Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.

  Magnetic resonance in medicine 20080701

• Early impairment of myocardial function in young patients with beta-thalassemia major.

  European journal of haematology 20080601

• UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

  British journal of clinical pharmacology 20080601

• Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells.

  Journal of neurochemistry 20080601

• Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis.

  British journal of haematology 20080601

• The labile iron pool in human erythroid cells.

  British journal of haematology 20080601

• Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.

  European journal of medicinal chemistry 20080501

• Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

  Haematologica 20080501

• Chelation of bismuth by combining desferrioxamine and deferiprone in rats.

  Toxicology and industrial health 20080501

• The involvement of lysosomes in myocardial aging and disease.

  Current cardiology reviews 20080501

• Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation.

  Movement disorders : official journal of the Movement Disorder Society 20080430

• A new lactoferrin- and iron-dependent lysosomal death pathway is induced by benzo[a]pyrene in hepatic epithelial cells.

  Toxicology and applied pharmacology 20080415

• The fenton activity of iron(III) in the presence of deferiprone.

  Journal of pharmaceutical sciences 20080401

• What is new in iron overload?

  European journal of pediatrics 20080401

• Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone.

  Journal of inorganic biochemistry 20080401

• Oral iron chelators.

  Pediatric clinics of North America 20080401

• Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major.

  Hematology (Amsterdam, Netherlands) 20080401

• Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

  European journal of clinical investigation 20080301

• Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.

  Pharmacotherapy 20080301

• Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode.

  Analytical biochemistry 20080215

• Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment.

  American journal of hematology 20080201

• Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications.

  Blood 20080201

• Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

  European journal of haematology 20080201

• The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.

  European journal of haematology 20080201

• Transfusion-dependent thalassaemia: a new era.

  The Medical journal of Australia 20080121

• Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.

  The Medical journal of Australia 20080121

• Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.

  The Biochemical journal 20080115

• Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera.

  Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20080101

• Flow cytometry measurement of the labile iron pool in human hematopoietic cells.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20080101

• Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.

  Hemoglobin 20080101

• Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.

  Hemoglobin 20080101

• Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.

  Hemoglobin 20080101

• Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.

  Hemoglobin 20080101

• Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.

  Hemoglobin 20080101

• Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.

  Hemoglobin 20080101

• A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.

  Hemoglobin 20080101

• The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats.

  Hemoglobin 20080101

• Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.

  Hemoglobin 20080101

• Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20080101

• Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20080101

• Synthesis, Spectroscopic, and Anticancerous Properties of Mixed Ligand Palladium(II) and Silver(I) Complexes with 4,6-Diamino-5-hydroxy-2-mercaptopyrimidine and 2,2'-Bipyridyl.

  Metal-based drugs 20080101

• Fatal congestive heart failure with deferiprone.

  Gastroenterologie clinique et biologique 20080101

• Deferiprone targets aconitase: implication for Friedreich's ataxia treatment.

  BMC neurology 20080101

• Body iron metabolism and pathophysiology of iron overload.

  International journal of hematology 20080101

• Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20080101

• Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].

  Hemoglobin 20080101

• Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.

  Hemoglobin 20080101

• Protecting academic freedom.

  Open medicine : a peer-reviewed, independent, open-access journal 20080101

• MRI evaluation of tissue iron burden in patients with beta-thalassaemia major.

  Pediatric radiology 20071201

• Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.

  Hematology (Amsterdam, Netherlands) 20071201

• Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda.

  Hepatology (Baltimore, Md.) 20071201

• Iron loading and its clinical implications.

  American journal of hematology 20071201

• Concepts and goals in the management of transfusional iron overload.

  American journal of hematology 20071201

• Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.

  European journal of haematology 20071201

• Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.

  Leukemia research 20071201

• A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.

  Haematologica 20071201

• comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.

  International journal of hematology 20071201

• Hypoparathyroidism in adult patients with Beta-thalassemia major.

  Sultan Qaboos University medical journal 20071201

• Lanthanide containing compounds for therapeutic care in bone resorption disorders.

  Dalton transactions (Cambridge, England : 2003) 20071121

• Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20071101

• pH indicator titration: a novel fast pKa determination method.

  Journal of pharmaceutical sciences 20071001

• Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

  Cell proliferation 20071001

• Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

  Transfusion 20071001

• Deferiprone: second-line treatment of iron overload in the absence of a better alternative.

  Prescrire international 20071001

• Deferasirox: for iron overload: only a third-line option.

  Prescrire international 20071001

• Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine.

  International journal of hematology 20071001

• Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

  Therapeutics and clinical risk management 20071001

• Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.

  Journal of pediatric hematology/oncology 20070901

• Hemoglobin is a co-factor of human trypanosome lytic factor.

  PLoS pathogens 20070901

• Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20070901

• Coordination chemistry and biology of chelators for the treatment of iron overload disorders.

  Dalton transactions (Cambridge, England : 2003) 20070814

• Iron chelation, quo vadis?

  Current opinion in chemical biology 20070801

• Light and shadows in the iron chelation treatment of haematological diseases.

  British journal of haematology 20070801

• Current status of iron overload and chelation with deferasirox.

  Indian journal of pediatrics 20070801

• Deferasirox: the new oral iron chelator.

  Indian pediatrics 20070801

• Oral deferiprone for iron chelation in people with thalassaemia.

  The Cochrane database of systematic reviews 20070718

• Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

  Blood 20070701

• Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.

  Blood 20070615

• Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

  European journal of haematology 20070601

• Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.

  Journal of avian medicine and surgery 20070601

• Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).

  Journal of avian medicine and surgery 20070601

• Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.

  Therapeutics and clinical risk management 20070601

• Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.

  Expert opinion on drug safety 20070501

• Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20070501

• A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

  Circulation 20070410

• Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.

  Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20070401

• Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.

  Diabetes research and clinical practice 20070401

• Deferiprone: agranulocytosis and neurological disorders.

  Prescrire international 20070401

• Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.

  European journal of heart failure 20070301

• Chelation therapy for iron overload.

  Current gastroenterology reports 20070301

• Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic macrophages.

  The Journal of biological chemistry 20070223

• Commentary: Science scandal or ethics scandal? Olivieri redux.

  Bioethics 20070201

• Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).

  Blood 20070101

• Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.

  European journal of haematology 20070101

• Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy.

  European journal of haematology 20070101

• Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy.

  The Journal of infectious diseases 20070101

• Red cell adhesion in cerebral malaria.

  The Indian journal of medical research 20070101

• Recent developments in iron chelation therapy.

  Klinische Padiatrie 20070101

• Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.

  Hemoglobin 20070101

• Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major.

  Hormones (Athens, Greece) 20070101

• [Post transfusionnal iron overload].

  La Revue du praticien 20061215

• An in vitro study of interactions between insulin-mimetic zinc(II) complexes and selected plasma components.

  Journal of inorganic biochemistry 20061201

• Physical growth patterns and dental caries in thalassemia.

  Indian pediatrics 20061201

• Protective effect of monosialoganglioside GM1 against chemically induced apoptosis through targeting of mitochondrial function and iron transport.

  Biochemical pharmacology 20061115

• Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

  Blood 20061101

• Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

  The Journal of antimicrobial chemotherapy 20061101

• Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

  Translational research : the journal of laboratory and clinical medicine 20061101

• Chelation therapy and bone metabolism markers in thalassemia major.

  Journal of pediatric endocrinology & metabolism : JPEM 20061101

• Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.

  Acta pharmacologica Sinica 20061001

• Fenton chemistry and iron chelation under physiologically relevant conditions: Electrochemistry and kinetics.

  Chemical research in toxicology 20061001

• Deferasirox: An effective once-daily orally active iron chelator.

  Drugs of today (Barcelona, Spain : 1998) 20061001

• Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.

  Haematologica 20060901

• A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.

  Haematologica 20060901

• Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.

  British journal of haematology 20060801

• Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.

  Human & experimental toxicology 20060701

• Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.

  Haematologica 20060601

• Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.

  Haematologica 20060601

• Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

  Haematologica 20060601

• Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

  Blood 20060501

• Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

  Blood 20060501

• Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.

  Annals of hematology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

  Blood 20060501

• Monensin improves the effectiveness of meso-dimercaptosuccinate when used to treat lead intoxication in rats.

  Environmental health perspectives 20060401

• Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease.

  British journal of haematology 20060401

• New lipophilic 3-hydroxy-4-pyridinonate iron(III) complexes: synthesis and EXAFS structural characterisation.

  Dalton transactions (Cambridge, England : 2003) 20060314

• Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

  European journal of haematology 20060301

• New chelation therapies and emerging chelating drugs for the treatment of iron overload.

  Expert opinion on emerging drugs 20060301

• Quantum chemical analysis of the deferiprone-iron binding reaction.

  International journal of nanomedicine 20060301

• Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives.

  Journal of medicinal chemistry 20060112

• Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.

  Blood cells, molecules & diseases 20060101

• Myelodysplastic syndromes: iron overload consequences and current chelating therapies.

  Journal of the National Comprehensive Cancer Network : JNCCN 20060101

• [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].

  Revista espanola de cardiologia 20060101

• PCTH: a novel orally active chelator for the treatment of iron overload disease.

  Hemoglobin 20060101

• Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.

  Hemoglobin 20060101

• Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.

  Hemoglobin 20060101

• Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.

  Hemoglobin 20060101

• Protoporphyrin IX level correlates with number of mitochondria, but increase in production correlates with tumor cell size.

  Photochemistry and photobiology 20060101

• Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.

  Hemoglobin 20060101

• Radiation protection by deferiprone in animal models.

  Hemoglobin 20060101

• Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.

  Hemoglobin 20060101

• Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.

  Hemoglobin 20060101

• Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.

  Hemoglobin 20060101

• Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.

  Hemoglobin 20060101

• Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

  Hemoglobin 20060101

• Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.

  Hemoglobin 20060101

• Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.

  Hemoglobin 20060101

• A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.

  Hemoglobin 20060101

• Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.

  Hemoglobin 20060101

• Pilot study on the 'quality of life' as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.

  Hemoglobin 20060101

• Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.

  Hemoglobin 20060101

• Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload.

  Hemoglobin 20060101

• Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.

  Hemoglobin 20060101

• The impact of iron overload and its treatment on quality of life: results from a literature review.

  Health and quality of life outcomes 20060101

• Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

  Blood 20051101

• Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

  The Cochrane database of systematic reviews 20051019

• Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.

  European journal of haematology 20051001

• Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy.

  British journal of haematology 20051001

• New therapies for sickle cell disease.

  Hematology/oncology clinics of North America 20051001

• Combined therapy with deferiprone and desferrioxamine in thalassemia major.

  Haematologica 20051001

• Combined therapy with deferiprone and desferrioxamine in thalassemia major.

  Haematologica 20051001

• Tris(pyronato)- and tris(pyridonato)-ruthenium(III) complexes and solution NMR studies.

  Inorganic chemistry 20050919

• Beta-thalassemia.

  The New England journal of medicine 20050915

• The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits.

  Journal of inorganic biochemistry 20050801

• Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with 67Ga.

  Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20050801

• Deferiprone as an oral iron chelator in sickle cell disease.

  Annals of hematology 20050701

• Polyamine-vectored iron chelators: the role of charge.

  Journal of medicinal chemistry 20050616

• LPI-labile plasma iron in iron overload.

  Best practice & research. Clinical haematology 20050601

• Deferiprone therapy for transfusional iron overload.

  Best practice & research. Clinical haematology 20050601

• Long-term treatment with deferiprone in a L1 veteran.

  European journal of haematology 20050601

• Iron mobilisation from transferrin by deferiprone (L1).

  British journal of haematology 20050401

• Monitoring and treatment of iron overload: state of the art and new approaches.

  Seminars in hematology 20050401

• Treating iron overload: the state of the art.

  Seminars in hematology 20050401

• Synthesis, characterization, and structures of Mn(DMHP)3 x 12H2O and Mn(DMHP)2Cl x 0.5H2O.

  Inorganic chemistry 20050321

• Safety of oral iron chelator deferiprone in young thalassaemics.

  European journal of haematology 20050301

• Iron chelation therapy.

  Current hematology reports 20050301

• 9,10-Phenanthraquinone in diesel exhaust particles downregulates Cu,Zn-SOD and HO-1 in human pulmonary epithelial cells: intracellular iron scavenger 1,10-phenanthroline affords protection against apoptosis.

  Free radical biology & medicine 20050201

• Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.

  European journal of haematology 20050201

• Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.

  Indian pediatrics 20050201

• Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.

  European journal of haematology 20050101

• The Egyptian experience with oral iron chelators.

  Hematology (Amsterdam, Netherlands) 20050101

• Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.

  Acta haematologica 20050101

• Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

  Current medicinal chemistry 20050101

• Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

  Current medicinal chemistry 20050101

• Chelating agents used for plutonium and uranium removal in radiation emergency medicine.

  Current medicinal chemistry 20050101

• Chelators as antidotes of metal toxicity: therapeutic and experimental aspects.

  Current medicinal chemistry 20050101

• The Olivieri case: lessons for Australasia.

  Journal of bioethical inquiry 20050101

• Objectives and mechanism of iron chelation therapy.

  Annals of the New York Academy of Sciences 20050101

• Deferiprone: New insight.

  Annals of the New York Academy of Sciences 20050101

• Combined therapy with deferoxamine and deferiprone.

  Annals of the New York Academy of Sciences 20050101

• Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

  Annals of the New York Academy of Sciences 20050101

• T2* magnetic resonance and myocardial iron in thalassemia.

  Annals of the New York Academy of Sciences 20050101

• Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.

  Journal of Ayub Medical College, Abbottabad : JAMC 20050101

• Synthesis, structure, and solution dynamics of UO22+-hydroxy ketone compounds [UO2(ma)2(H2O)] and [UO2(dpp)(Hdpp)2(H2O)]ClO4 [ma = 3-hydroxy-2-methyl-4-pyrone, Hdpp = 3-hydroxy-1,2-dimethyl-4(1H)-pyridone].

  Inorganic chemistry 20041227

• PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.

  Biochimica et biophysica acta 20041224

• Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20041201

• Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.

  Hematology/oncology clinics of North America 20041201

• Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.

  Pediatric endocrinology reviews : PER 20041201

• Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia.

  British journal of haematology 20041101

• Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.

  AJR. American journal of roentgenology 20041001

• Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.

  Blood 20040901

• The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

  Current medicinal chemistry 20040801

• Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.

  Annals of hematology 20040701

• Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia.

  Journal of pediatric hematology/oncology 20040701

• Purging iron from the heart.

  British journal of haematology 20040601

• Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

  Gut 20040501

• Magnetic-field-induced DNA strand breaks in brain cells of the rat.

  Environmental health perspectives 20040501

• Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.

  Biochemical pharmacology 20040415

• Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.

  Haematologica 20040401

• Independent clinical trials.

  Lancet (London, England) 20040327

• Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase.

  American journal of physiology. Heart and circulatory physiology 20040301

• Deferiprone, efficacy and safety.

  Indian journal of pediatrics 20040301

• Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.

  Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 20040301

• CJEC 2004/2, case T-326/99, Olivieri/Commisssion.

  European journal of health law 20040301

• Thalassaemia major: the murky story of deferiprone.

  BMJ (Clinical research ed.) 20040214

• Introduction to The Olivieri symposium.

  Journal of medical ethics 20040201

• Whistleblower vows to fight on.

  BMJ (Clinical research ed.) 20040124

• Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs.

  Journal of bone and mineral metabolism 20040101

• Iron: a target for the management of Kaposi's sarcoma?

  BMC cancer 20040101

• Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

  Blood cells, molecules & diseases 20040101

• Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.

  Indian pediatrics 20040101

• Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.

  Acta haematologica 20040101

• Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines.

  Anticancer research 20040101

• Iron-chelation therapy: an update.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Thalassemia.

  Hematology. American Society of Hematology. Education Program 20040101

• Five-year trial of deferiprone chelation therapy in thalassaemia major patients.

  Acta haematologica 20040101

• Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives.

  Bioorganic & medicinal chemistry letters 20031215

• Polyamine-iron chelator conjugate.

  Journal of medicinal chemistry 20031204

• Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.

  Haematologica 20031201

• Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

  Blood 20031001

• Pharmacotherapy of iron overload in thalassaemic patients.

  Expert opinion on pharmacotherapy 20031001

• Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

  Blood 20030901

• Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.

  Mutagenesis 20030901

• Do we need more iron-chelating drugs?

  Lancet (London, England) 20030809

• Pulmonary dysfunction in transfusion-dependent patients with thalassemia major.

  American journal of respiratory and critical care medicine 20030715

• Role of deferiprone in chelation therapy for transfusional iron overload.

  Blood 20030701

• Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice.

  Gynecologic oncology 20030701

• Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.

  British journal of haematology 20030701

• Deferiprone and hepatic fibrosis.

  Blood 20030615

• Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.

  Inorganic chemistry 20030602

• Iron chelator research: past, present, and future.

  Current medicinal chemistry 20030601

• Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload.

  Current medicinal chemistry 20030601

• Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.

  European journal of haematology 20030601

• Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.

  British journal of haematology 20030601

• Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease.

  Alcohol (Fayetteville, N.Y.) 20030601

• Signaling role of intracellular iron in NF-kappaB activation.

  The Journal of biological chemistry 20030516

• Glutathione depletion increases nitric oxide-induced oxidative stress in primary rat hepatocyte cultures: involvement of low-molecular-weight iron.

  Free radical biology & medicine 20030515

• Treatment of cardiac iron overload in thalassemia major.

  Haematologica 20030501

• Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

  Haematologica 20030501

• Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.

  Hemoglobin 20030501

• Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.

  British journal of haematology 20030401

• Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.

  European journal of biochemistry 20030401

• The Olivieri case.

  The New England journal of medicine 20030227

• The Olivieri case.

  The New England journal of medicine 20030227

• Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

  Lancet (London, England) 20030111

• Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

  Lancet (London, England) 20030111

• Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

  Lancet (London, England) 20030111

• Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

  Lancet (London, England) 20030111

• Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.

  Acta haematologica 20030101

• Patients' health or company profits? The commercialisation of academic research.

  Science and engineering ethics 20030101

• The Olivieri Report--a compelling study of the growing tensions in clinical research.

  Science and engineering ethics 20030101

• [Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101

• Iron chelating agents for treating malaria.

  The Cochrane database of systematic reviews 20030101

• Clinical research: a tale of two studies.

  Transactions of the American Clinical and Climatological Association 20030101

• Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

  Drug safety 20030101

• Iron chelation in chemotherapy.

  Advances in applied microbiology 20030101

• Iron deficiency and overload.

  Hematology. American Society of Hematology. Education Program 20030101

• Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.

  Acta haematologica 20030101

• Objectives and methods of iron chelation therapy.

  Bioinorganic chemistry and applications 20030101

• Experience with the oral iron chelator deferiprone in transfusion-dependent children.

  The Ceylon medical journal 20021201

• Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives.

  Journal of enzyme inhibition and medicinal chemistry 20021201

• Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.

  Bioorganic & medicinal chemistry letters 20021118

• Academic freedom in clinical research.

  The New England journal of medicine 20021024

• Iron toxicity and chelation therapy.

  International journal of hematology 20021001

• Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.

  Blood 20020901

• Microbial growth-promotion activity of 3-hydroxymonoazine- and N-hydroxydiazine-type heterocycles.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20020901

• Deferiprone: greater efficacy at depleting myocardial than hepatic iron?

  Lancet (London, England) 20020817

• Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

  Lancet (London, England) 20020817

• The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro.

  International journal of cancer 20020801

• Different complexation properties of some hydroxy keto heterocycles toward beryllium(II) in aqueous solutions: experimental and theoretical studies.

  Inorganic chemistry 20020729

• Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.

  Free radical biology & medicine 20020715

• I beg to differ.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020709

• Independent inquiry.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020709

• The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.

  British journal of haematology 20020701

• Orally active iron chelators.

  Blood reviews 20020601

• Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.

  Gynecologic oncology 20020401

• A postmodern moral tale: the ethics of research relationships.

  Nature reviews. Drug discovery 20020401

• The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.

  Toxicology letters 20020310

• News article on report about drug researcher was biased.

  BMJ (Clinical research ed.) 20020309

• Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.

  European journal of clinical investigation 20020301

• Dances with the pharmaceutical industry.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020219

• The deferiprone controversy: time to move on.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020219

• The Olivieri dispute: no end in sight?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020219

• Iron regulation of hepatic macrophage TNFalpha expression.

  Free radical biology & medicine 20020215

• Treatment of thalassoemia--the current scenario.

  Journal of the Indian Medical Association 20020201

• Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.

  Journal of medicinal chemistry 20020131

• Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.

  Journal of inorganic biochemistry 20020115

• Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.

  Arzneimittel-Forschung 20020101

• The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.

  The Journal of laboratory and clinical medicine 20020101

• An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.

  BMC clinical pharmacology 20020101

• Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients.

  Haematologia 20020101

• Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

  Blood cells, molecules & diseases 20020101

• Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.

  Acta haematologica 20020101

• Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.

  The Indian journal of medical research 20020101

• Long term deferiprone chelation therapy.

  Advances in experimental medicine and biology 20020101

• Antimalarial effect of iron chelators.

  Advances in experimental medicine and biology 20020101

• Industry and the academy: conflicts of interest in contemporary health research.

  Health law journal 20020101

• Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase.

  The Journal of biological chemistry 20011228

• Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.

  Blood 20011215

• Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1).

  Biochemical pharmacology 20011215

• Report clears researcher who broke drug company agreement.

  BMJ (Clinical research ed.) 20011110

• Chelation therapy in beta-thalassemia: an optimistic update.

  Seminars in hematology 20011001

• [Iron overload and myelodysplastic syndromes].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20011001

• Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.

  The Journal of laboratory and clinical medicine 20010801

• Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.

  European journal of haematology 20010701

• Olivieri to testify against Apotex in Europe.

  Nature medicine 20010601

• Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• The controversial role of deferiprone in the treatment of thalassemia.

  The Journal of laboratory and clinical medicine 20010501

• [Therapeuetic management of patients with thalassemia major].

  Bulletin de la Societe de pathologie exotique (1990) 20010501

• Deferiprone or fatal iron toxic effects?

  Lancet (London, England) 20010317

• Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

  Blood 20010201

• Radiation sensitization of mammalian cells by metal chelators.

  Radiation research 20010201

• Genotoxicity of iron chelators in L5178Y mouse lymphoma cells.

  Environmental and molecular mutagenesis 20010101

• Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity.

  Arzneimittel-Forschung 20010101

• Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.

  The Journal of infectious diseases 20000201

• Characterization of iron uptake from transferrin by murine endothelial cells.

  Endothelium : journal of endothelial cell research 20000101

• Antiproliferative effect of deferiprone on the Hep G2 cell line.

  Biochemical pharmacology 19980815

• Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1).

  Biochemical pharmacology 19980601

• Iron chelators as therapeutic agents against Pneumocystis carinii.

  Antimicrobial agents and chemotherapy 19940501